Varian to Acquire Oncozene and Embozene Embolic Bead Lines From Boston Scientific

 

July 2, 2019—Varian Medical Systems, Inc. continued to expand its interventional oncology/embolic portfolio, announcing plans to acquire Boston Scientific's drug-loadable microsphere and bland embolic bead product lines for treating arteriovenous malformations and hypervascular tumors. On June 10, Varian acquired Endocare, an Austin-based cryotherapy business, and embolic manufacturer Alicon, located in China.

The Boston Scientific assets include the Oncozene/Embozene Tandem drug-loadable microspheres and Embozene bland embolics, which Varian notes have regulatory clearance in more than 35 countries.

Varian states that it will not acquire any Boston Scientific operations in the transaction and will work with the company under transition services agreements to ensure uninterrupted product delivery while it implements manufacturing and distribution plans. The transaction is anticipated to close around August 2019, although it must clear customary conditions and the closing of Boston Scientific's BTG acquisition. Jeff Mirviss, Boston Scientific's Global President for Peripheral Interventions, commented to Endovascular Today that the divestiture is intended to address antitrust concerns with certain regulatory authorities, including the Federal Trade Commission.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.